Panelists discuss how patients with early recurrent low-grade bladder cancer, especially those on an anticoagulant or with multiple risk factors, represent ideal candidates for ablative therapy with UGN-102 to break the cycle of repeated transurethral resection of bladder tumors (TURBTs) and provide a paradigm shift from purely surgical management to shared decision-making between surgical and medical treatment options.
Panelists discuss how patients with recurrent low-grade bladder cancer, particularly women who may face additional anatomical challenges during transurethral resection of bladder tumor (TURBT) procedures, can benefit from UGN-102 as an alternative to repetitive surgical resections, addressing the TURBT treadmill phenomenon where patients undergo multiple procedures with diminishing returns.
Panelists discuss how UGN-102, a reverse thermal hydrogel formulation of mitomycin, offers an FDA-approved ablative treatment option for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), demonstrating 80% complete response rates in the ENVISION trial (NCT05243550) and allowing for the de-escalation of surveillance and reduced surgical burden.
"As clinicians for patients requiring cancer care, we need to ensure that we are optimizing all precautions for both the elderly and for those with potential immunosuppression," writes Neal D. Shore, MD.
Published: March 27th 2020 | Updated:
